Next phase of the High-Risk Plaque Initiative will leverage advances in diagnostic imaging and blood biomarker science to reduce morbidity, mortality and cost associated with cardiovascular disease

Quanterix Technology Shown To Be More Than 1,000 Times More Sensitive Than Standard Methods With Potential For Broad Application To Measure Biomarkers In Cancer, Autoimmune, and Neurological Diseases

Physic Ventures Leads Financing in Novel Technology to Enable Decentralized Diagnostics

CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors.

Cambridge, MA -- January 3, 2008 – T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance imaging (MRI) technology, today announced the appointment of John McDonough as Chief Executive Officer. McDonough will also serve as a member of the Company’s board of directors.

CAMBRIDGE, Mass., Jan 04, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation announced today that it has closed a $20 million senior secured credit facility with GE Healthcare Financial Services. The Company will use the credit facility to support working capital and commercialization efforts.

Success Attributed to Carbon Model Studio Launch, New Customers, Partnerships with ARM, CoWare; Plans Move to New Corporate Headquarters to Support Hiring

WALTHAM, Mass.--(BUSINESS WIRE)--Carbon Design Systems™, the leading supplier of tools for the automatic creation, validation and deployment of virtual hardware models, today announced it has closed a round of funding totaling $6 million, after a successful Fiscal Year 2007.

Partnership with Dr. Victor Ambros to Expand Genomic Discoveries

CAMBRIDGE, Mass., Jan 09, 2008 (BUSINESS WIRE) -- Helicos BioSciences (Nasdaq:HLCS), a life science company focused on innovative genetic analysis technologies, announced today a formal collaboration with Dr. Victor Ambros to apply the quantitative power of True Single Molecule Sequencing (tSMS(TM)) to develop a single assay to characterize known species of microRNA (miRNA) as well as discover new non-coding RNAs.

Pioneer in regenerative cell-based therapies and devices announces additional funding in support of Vascugel® blood vessel repair therapeutic clinical trials and research into additional vascular and non-vascular disease applications

January 23, 2008 -- Waltham, Mass. BG Medicine, a medical diagnostics company, announced today that based on current market conditions, it has chosen not to proceed with its planned initial public offering at this time. The company has withdrawn its registration statement on Form S-1 as filed with the Securities and Exchange Commission.